论文部分内容阅读
目的:探讨孟鲁司特联合沙美特罗替卡松治疗支气管哮喘的临床疗效。方法:选取近期来我院进行治疗的支气管哮喘患者100例,采取国际通用随机字母表法将入组患者分为两组,观察组和对照组均包含50例。对照组患者给予沙美特罗替卡松(舒利迭)吸入进行治疗,观察组患者给予孟鲁司特(顺尔宁)联合沙美特罗替卡松进行治疗。结果:观察组和对照组患者的临床治疗总有效率分别为92.0%和90.0%,组间比较差异不具有统计学意义(P>0.05)。观察组和对照组患者治疗后ACT和PEF均得到了显著改善,且改善程度相当,组间比较差异不具有统计学意义(P>0.05)。两组患者在临床治疗期间均未出现较为严重的不良反应。结论:小剂量吸入沙美特罗替卡松联合口服孟鲁司特治疗支气管哮喘能够取得与单纯大剂量吸入沙美特罗替卡松相当的临床效果,并且对患者的哮喘症状和肺功能均有显著的改善作用,且临床治疗安全性较好。
Objective: To investigate the clinical efficacy of montelukast combined with salmeterol and fluticasone in the treatment of bronchial asthma. Methods: A total of 100 patients with bronchial asthma who were treated in our hospital recently were enrolled. Patients were divided into two groups according to the international random alphabet method. The observation group and the control group included 50 cases. Patients in the control group were treated with salmeterol / tamsulosin (seretide) inhalation, and patients in the observation group were treated with montelukast (salbutamol) combined with salmeterol / fluticasone. Results: The total effective rate of clinical treatment in observation group and control group was 92.0% and 90.0%, respectively. There was no significant difference between two groups (P> 0.05). After treatment, both ACT and PEF in observation group and control group were significantly improved, and the degree of improvement was similar, with no significant difference between the two groups (P> 0.05). Two groups of patients during the clinical treatment were not more serious adverse reactions. CONCLUSIONS: Small-dose inhaled salmeterol and ticutamide in combination with oral montelukast in the treatment of bronchial asthma is comparable in efficacy to high-dose inhaled salmeterol and tacrolimus and has significant effects on both asthma symptoms and lung function Improve the role, and the clinical treatment of safety is better.